Research  ||| S:0 E:9 ||| NN
efforts  ||| S:9 E:17 ||| NNS
to  ||| S:17 E:20 ||| TO
control  ||| S:20 E:28 ||| VB
highly  ||| S:28 E:35 ||| RB
pathogenic  ||| S:35 E:46 ||| JJ
arenaviruses ||| S:46 E:58 ||| NN
:  ||| S:58 E:60 ||| :
a  ||| S:60 E:62 ||| DT
summary  ||| S:62 E:70 ||| NN
of  ||| S:70 E:73 ||| IN
the  ||| S:73 E:77 ||| DT
progress  ||| S:77 E:86 ||| NN
and  ||| S:86 E:90 ||| CC
gaps  ||| S:90 E:95 ||| JJ
Significant  ||| S:95 E:107 ||| JJ
progress  ||| S:107 E:116 ||| NN
has  ||| S:116 E:120 ||| VBZ
been  ||| S:120 E:125 ||| VBN
made  ||| S:125 E:130 ||| VBN
in  ||| S:130 E:133 ||| IN
the  ||| S:133 E:137 ||| DT
past  ||| S:137 E:142 ||| JJ
10  ||| S:142 E:145 ||| CD
years  ||| S:145 E:151 ||| NNS
in  ||| S:151 E:154 ||| IN
unraveling  ||| S:154 E:165 ||| VBG
the  ||| S:165 E:169 ||| DT
molecular  ||| S:169 E:179 ||| JJ
biology  ||| S:179 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
highly  ||| S:190 E:197 ||| RB
pathogenic  ||| S:197 E:208 ||| JJ
arenaviruses  ||| S:208 E:221 ||| NN
that  ||| S:221 E:226 ||| WDT
are  ||| S:226 E:230 ||| VBP
endemic  ||| S:230 E:238 ||| VBN
in  ||| S:238 E:241 ||| IN
several  ||| S:241 E:249 ||| JJ
West  ||| S:249 E:254 ||| JJ
African  ||| S:254 E:262 ||| JJ
countries  ||| S:262 E:272 ||| NNS
( ||| S:272 E:273 ||| -LRB-
Lassa  ||| S:273 E:279 ||| NNP
fever  ||| S:279 E:285 ||| NN
virus ||| S:285 E:290 ||| NN
)  ||| S:290 E:292 ||| -RRB-
and  ||| S:292 E:296 ||| CC
in  ||| S:296 E:299 ||| IN
some  ||| S:299 E:304 ||| DT
regions  ||| S:304 E:312 ||| NNS
of  ||| S:312 E:315 ||| IN
South  ||| S:315 E:321 ||| NNP
America  ||| S:321 E:329 ||| NNP
( ||| S:329 E:330 ||| -LRB-
Argentine  ||| S:330 E:340 ||| NNP
and  ||| S:340 E:344 ||| CC
Bolivian  ||| S:344 E:353 ||| NNP
hemorrhagic  ||| S:353 E:365 ||| FW
fever  ||| S:365 E:371 ||| FW
viruses ||| S:371 E:378 ||| FW
) ||| S:378 E:379 ||| -RRB-
.  ||| S:379 E:381 ||| .
While  ||| S:381 E:387 ||| IN
this  ||| S:387 E:392 ||| DT
has  ||| S:392 E:396 ||| VBZ
resulted  ||| S:396 E:405 ||| VBN
in  ||| S:405 E:408 ||| IN
proof-of-concept  ||| S:408 E:425 ||| JJ
studies  ||| S:425 E:433 ||| NNS
of  ||| S:433 E:436 ||| IN
novel  ||| S:436 E:442 ||| NN
vaccine  ||| S:442 E:450 ||| NN
candidates  ||| S:450 E:461 ||| NNS
in  ||| S:461 E:464 ||| IN
non-human  ||| S:464 E:474 ||| JJ
primates  ||| S:474 E:483 ||| NN
and  ||| S:483 E:487 ||| CC
in  ||| S:487 E:490 ||| IN
the  ||| S:490 E:494 ||| DT
discovery  ||| S:494 E:504 ||| NN
of  ||| S:504 E:507 ||| IN
several  ||| S:507 E:515 ||| JJ
novel  ||| S:515 E:521 ||| NN
antiviral  ||| S:521 E:531 ||| JJ
small  ||| S:531 E:537 ||| JJ
molecule  ||| S:537 E:546 ||| NN
drug  ||| S:546 E:551 ||| NN
candidates ||| S:551 E:561 ||| NNS
,  ||| S:561 E:563 ||| ,
none  ||| S:563 E:568 ||| NN
of  ||| S:568 E:571 ||| IN
them  ||| S:571 E:576 ||| PRP
has  ||| S:576 E:580 ||| VBZ
been  ||| S:580 E:585 ||| VBN
tested  ||| S:585 E:592 ||| VBN
in  ||| S:592 E:595 ||| IN
the  ||| S:595 E:599 ||| DT
clinic  ||| S:599 E:606 ||| NN
to  ||| S:606 E:609 ||| TO
date ||| S:609 E:613 ||| NN
.  ||| S:613 E:615 ||| .
The  ||| S:615 E:619 ||| DT
recent  ||| S:619 E:626 ||| JJ
Ebola  ||| S:626 E:632 ||| JJ
outbreak  ||| S:632 E:641 ||| NN
in  ||| S:641 E:644 ||| IN
West  ||| S:644 E:649 ||| NNP
Africa  ||| S:649 E:656 ||| NNP
has  ||| S:656 E:660 ||| VBZ
demonstrated  ||| S:660 E:673 ||| VBN
very  ||| S:673 E:678 ||| RB
clearly  ||| S:678 E:686 ||| RB
that  ||| S:686 E:691 ||| IN
there  ||| S:691 E:697 ||| EX
is  ||| S:697 E:700 ||| VBZ
an  ||| S:700 E:703 ||| DT
urgent  ||| S:703 E:710 ||| JJ
need  ||| S:710 E:715 ||| NN
to  ||| S:715 E:718 ||| TO
develop  ||| S:718 E:726 ||| VB
the  ||| S:726 E:730 ||| DT
prophylactic  ||| S:730 E:743 ||| NN
and  ||| S:743 E:747 ||| CC
therapeutic  ||| S:747 E:759 ||| JJ
armamentarium  ||| S:759 E:773 ||| NN
against  ||| S:773 E:781 ||| IN
viral  ||| S:781 E:787 ||| JJ
hemorrhagic  ||| S:787 E:799 ||| JJ
fever  ||| S:799 E:805 ||| NN
viruses  ||| S:805 E:813 ||| NN
as  ||| S:813 E:816 ||| IN
part  ||| S:816 E:821 ||| NN
of  ||| S:821 E:824 ||| IN
a  ||| S:824 E:826 ||| DT
global  ||| S:826 E:833 ||| JJ
preparedness  ||| S:833 E:846 ||| NN
for  ||| S:846 E:850 ||| IN
future  ||| S:850 E:857 ||| JJ
epidemics ||| S:857 E:866 ||| NN
.  ||| S:866 E:868 ||| .
As  ||| S:868 E:871 ||| IN
it  ||| S:871 E:874 ||| PRP
pertains  ||| S:874 E:883 ||| VBP
to  ||| S:883 E:886 ||| TO
this  ||| S:886 E:891 ||| DT
goal ||| S:891 E:895 ||| NN
,  ||| S:895 E:897 ||| ,
the  ||| S:897 E:901 ||| DT
present  ||| S:901 E:909 ||| JJ
article  ||| S:909 E:917 ||| NN
summarizes  ||| S:917 E:928 ||| VBD
the  ||| S:928 E:932 ||| DT
current  ||| S:932 E:940 ||| JJ
knowledge  ||| S:940 E:950 ||| NN
of  ||| S:950 E:953 ||| IN
highly  ||| S:953 E:960 ||| RB
pathogenic  ||| S:960 E:971 ||| JJ
arenaviruses  ||| S:971 E:984 ||| NN
and  ||| S:984 E:988 ||| CC
identifies  ||| S:988 E:999 ||| JJ
opportunities  ||| S:999 E:1013 ||| NNS
for  ||| S:1013 E:1017 ||| IN
translational  ||| S:1017 E:1031 ||| JJ
research ||| S:1031 E:1039 ||| NN
.  ||| S:1039 E:1041 ||| .
